Stocks Fall BioTech ETF still Up YTD

Bull Wall St Stockmasters Logo

Despite Friday's fall BioTech is still up.

After last week's major decline the Dow Jones is now negative for the year, the S&P 500 is only up 1%, but the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) is up 24% YTD.
The coveted BioTech ETF which trades under the ticker "IBB" has been a standout in 2015. Despite the volatile trading of the stocks that make up the index the IBB beat all the indexes in spades. In the past 12 months the IBB has gained 47%. BioTech is here to stay and made our Stocks to own for 2015 and Beyond (SHAK, IRBT, GOOG, DIS, IBB)
 
The IBB seeks to track the results of an index composed of biotech and pharmaceutical stocks listed on the Nasdaq. Morningstar rates it a five-star fund because of its extraordinary record of success and future potential.
 
Currently, the largest holdings in IBB are Gilead Sciences, Inc. (GILD), Amgen, Inc. (AMGN), Biogen Inc (BIIB), Celgene Corporation (CELG), Regeneron Pharmaceuticals Inc (REGN), Mylan NV (MYL), Illumina, Inc. (ILMN),Vertex Pharmaceuticals Incorporated (VRTX), Alexion Pharmaceuticals, Inc. (ALXN) and BioMarin Pharmaceutical Inc.(BMRN).
 
Mastery is taking the approach of why fight it? Just go with the IBB and shut your mouth.
IBB iShares Nasdaq Biotechnology daily Stock Chart